|NextSeq 550 System||RNA Profiling: 6-20 samples per run (based on 20 million reads per
Transcriptome Analysis: 2-8 samples per run (based on 50 million reads per sample)
|2 x 75 bp
2 x 75 bp
|HiSeq 2500 System||RNA Profiling: 30-200 samples per run (dual flow cell; based on 20
million reads per sample)
Transcriptome Analysis: 12-80 samples per run (dual flow cell; based on 50 million reads per sample)
|2 x 75 bp
2 x 75 bp
|NovaSeq 6000 System||RNA Profiling (samples per run, dual flow cell): S1: 160, S2: 320, S4:
768. Limited by index combinations (dual). Based on 20 million reads.
Transcriptome Analysis (samples per run, dual flow cell): S1: 64, S2: 128, S4: 400. Limited by index combinations (dual). Based on 50 million reads.
|≤ 2 × 100 bp
≤ 2 × 100 bp
Technical replicates of FFPE tissue show high concordance, indicating robust library prep performance. Axes are log2(FPKM). R2 value is shown.
TruSeq Stranded Total RNA gives excellent coverage across the top 1,000 expressed transcripts in both fresh-frozen (FF, top) and FFPE (bottom) tumor and matched normal breast tissue, with > 98% aligned stranded reads. X-axis: position along transcript, Y-axis = percent coverage of combined reads.
Limited Use Label License: The TruSeq Stranded Total RNA with Ribo-Zero Globin Workflow product and its use are the subject of one or more issued and/or pending U.S. and foreign patent applications owned by Max Planck Gesellschaft, exclusively licensed to New England Biolabs, Inc. and sublicensed to Illumina, Inc. The purchase of this product from Illumina, Inc., its affiliates, or its authorized resellers and distributors conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product by the buyer (whether the buyer is an academic or for profit entity). The purchase of this product does not convey a license under any claims in the foregoing patents or patent applications direct to producing the product. The buyer cannot sell or otherwise transfer this product or its components to a third party or otherwise use the product for the following COMMERICAL PURPOSES: (I) use of the product or its components in manufacturing; or (2) use of the product or its components for therapeutic or prophylactic purposes in human or animals.